Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Docetaxel in Advanced NSCLC
NCT03798743Phase 2Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Jan 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03798743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798743.